Brain Tumor Organoids Predict CAR T Cell Therapy Response
Brain Tumor Organoids Offer Hope for Personalized Glioblastoma Treatment
Philadelphia, PA – In a groundbreaking progress, researchers at the University of Pennsylvania have successfully used lab-grown organoids, created from glioblastoma (GBM) tumors, too accurately predict a patient’s response to CAR T cell therapy in real time.This innovative approach mirrors the actual tumor’s response within the patient’s brain, offering a powerful new tool for personalized treatment.
GBM, the most aggressive type of brain cancer in adults, has a devastating prognosis with limited treatment options. While CAR T cell therapy has shown promise in treating blood cancers, its effectiveness against solid tumors like GBM has been challenging. This new research, published in Cell Stem Cell, suggests a potential breakthrough.
“One of the biggest hurdles in treating GBM is the tumor’s complexity,” explains Dr. Guo-li Ming, co-senior author of the study and Perelman Professor of Neuroscience. “Our organoids capture this complexity by replicating the tumor’s microenvironment, something traditional models lack.”
The organoids are created from tiny pieces of a patient’s tumor removed during surgery. This allows researchers to test the effectiveness of CAR T cell therapy within weeks, while the patient recovers and before starting treatment.
Remarkably, the organoids accurately mirrored the patients’ responses to the dual-target CAR T cell therapy being tested in a Phase I clinical trial. If the organoid shrank after treatment, so did the patient’s actual tumor.
“This research demonstrates the immense potential of GBM organoids,” says Dr. Donald M. O’Rourke, co-senior author and John Templeton, Jr., MD Professor in Neurosurgery. “They can not only predict treatment response but also help us understand and mitigate the risk of neurotoxicity,a serious side effect of CAR T cell therapy.”
The organoids revealed similar levels of immune cytokines, indicating toxicity, in both the lab-grown models and the patients’ cerebrospinal fluid. These levels decreased after treatment, suggesting the organoids can accurately model neurotoxicity risk and guide clinicians in determining the optimal CAR T cell dose for each patient.
This breakthrough opens exciting new avenues for personalized GBM treatment. By accurately predicting individual responses to therapy, organoids could help clinicians tailor treatment plans, maximizing effectiveness while minimizing side effects.
The research team is optimistic about the future of this technology. “Our hope is to bring these organoids to the clinic to personalize patient treatment and deepen our understanding of how to defeat this complex and deadly cancer,” concludes Dr. O’Rourke.
this research was funded by the National Institutes of health and supported by the Institute for Regenerative Medicine and the GBM Translational Center of Excellence in the Abramson Cancer Center.
Brain Tumor Organoids: A New Era of Personalized glioblastoma Treatment?
NewsDirectory3.com
Philadelphia, Pennsylvania – Researchers at the University of Pennsylvania have achieved a significant breakthrough in the fight against glioblastoma (GBM), the most aggressive type of brain cancer. Using lab-grown organoids derived from patient tumors, they have developed a method to accurately predict a patient’s response to CAR T-cell therapy in real time.
This innovative approach, detailed in a recent study published in Cell Stem Cell, offers a promising new tool for personalized treatment. Professor Guo-li Ming, co-senior author and Perelman Professor of Neuroscience, explains the urgency for this advancement:
“GBM is incredibly complex, and traditional models haven’t been able to accurately replicate its intricacies. our organoids capture the tumor’s microenvironment, allowing for a more realistic depiction of how it might react to treatment.”
Creating these organoids involves taking tiny tumor samples from patients during surgery.This allows researchers to test the effectiveness of CAR T-cell therapy within weeks while the patient recovers. Remarkably,the organoids have proven to be highly accurate predictors of patient response,mirroring real-time tumor shrinkage or growth.
Dr. Donald M. O’Rourke, co-senior author and John Templeton, Jr., MD Professor in Neurosurgery, highlights the wider applications of this groundbreaking technology:
“Not only can these organoids predict treatment response, but they can also help us understand and mitigate the risk of neurotoxicity, a serious side effect of CAR T-cell therapy.
By analyzing immune cytokine levels in the organoids, researchers can accurately model neurotoxicity risk and guide clinicians in determining the optimal CAR T-cell dose for each patient.
The research team is deeply optimistic about the future potential of organoid technology.
“Our goal is to bring these organoids into the clinic so we can personalize patient treatment and ultimately win the battle against this devastating cancer,” concludes Dr. O’Rourke.
This research was generously funded by the National Institutes of Health and supported by the Institute for Regenerative Medicine and the GBM Translational Center of Excellence in the Abramson Cancer center.